Supraventricular tachycardia, or SVT, is the most common abnormal fast heart rhythm in newborns, causing the heart to race at rates often exceeding 220 beats per minute. The most frequent form involves an extra electrical pathway between the upper and lower chambers of the heart, creating a short-circuit loop that drives the heart far faster than normal.1Indian Pacing and Electrophysiology Journal. Neonatal supraventricular tachycardia While the diagnosis can be frightening for parents, the outlook is overwhelmingly positive: most babies respond well to treatment, and the majority outgrow SVT entirely within the first year of life.
What Happens During an SVT Episode
A normal newborn heart beats roughly 120 to 160 times per minute. During SVT, the rate can jump to 250 or even 300 beats per minute. At those speeds, the heart does not fill with blood properly between contractions, which means it pumps less efficiently. A brief episode may go unnoticed, but a prolonged one can stress the heart and, in rare cases, lead to heart failure if it is not recognized and treated.
The underlying mechanism in most neonatal SVT is a re-entry circuit. In the most common type, called atrioventricular re-entrant tachycardia, an abnormal extra electrical pathway connects the atria to the ventricles outside of the normal conduction system.2Indian Pacing and Electrophysiology Journal. Neonatal supraventricular tachycardia An electrical impulse races down one pathway and back up the other in a continuous loop, driving the heart at a dangerously fast rate. This is the same mechanism behind Wolff-Parkinson-White syndrome, which is one of the most recognized causes of SVT in infancy.
How SVT Is Recognized in a Newborn
Newborns cannot tell you something feels wrong, so SVT is often caught by a nurse or parent noticing that the baby looks “off.” Signs include unusual fussiness, pale or bluish skin, poor feeding, rapid breathing, or a general sense that the baby is lethargic. Sometimes the only clue is a heart rate alarm going off on a hospital monitor. In some cases, SVT is first diagnosed right at delivery when the initial heart rate check reveals a rate far above normal.3PubMed Central. Unexpected Rhythm: Supraventricular Tachycardia Unveiled in a Neonate Diagnosed at Delivery
The definitive diagnosis depends on a 12-lead electrocardiogram (ECG). SVT typically produces a narrow QRS complex on the tracing, meaning the electrical activity through the ventricles looks normal in width but fires at an abnormally fast rate.4PubMed Central. Common Supraventricular and Ventricular Arrhythmias in Children This narrow-complex pattern helps distinguish SVT from ventricular tachycardia, a different and potentially more dangerous rhythm that produces wider QRS complexes. When a wide QRS tachycardia is seen in a newborn, clinicians treat it as ventricular tachycardia unless there is strong evidence otherwise.5PubMed Central. Common Supraventricular and Ventricular Arrhythmias in Children
One diagnostic pitfall is telling SVT apart from sinus tachycardia, which is a fast heart rate caused by something else entirely, such as fever, pain, or infection. Sinus tachycardia speeds up and slows down gradually, while SVT snaps on and off abruptly. In rare cases, though, sinus tachycardia in sick newborns has been reported at rates of 240 to 270 beats per minute, overlapping with the SVT range and making the distinction tricky.6Progress in Pediatric Cardiology. Supraventricular tachycardia in the neonate and infant In those cases, the P-wave shape on the ECG and the clinical picture (those infants had sepsis) help sort things out.
When SVT Is Detected Before Birth
SVT can begin in the womb. It is the most common fetal tachyarrhythmia, and it is usually picked up during a routine ultrasound when the fetal heart rate is found to be abnormally fast.7PubMed Central. Successful medical treatment of fetal supraventricular tachycardia that cause hydrops fetalis Diagnosis is confirmed using specialized ultrasound techniques that visualize the timing of atrial and ventricular contractions.
Fetal SVT matters because it can lead to hydrops fetalis, a condition where fluid accumulates in the baby’s tissues and body cavities due to heart failure. This is a serious complication, but it does not mean treatment is hopeless. Doctors can administer anti-arrhythmic drugs to the mother, and those medications cross the placenta to treat the fetus. Drugs like digoxin, sotalol, and flecainide have all been used successfully in this setting.8PubMed Central. Successful medical treatment of fetal supraventricular tachycardia that cause hydrops fetalis In one reported case, a fetus with SVT and early hydrops at 26 weeks of gestation was treated with flecainide given to the mother. Within 24 hours of a dose increase, the fetal heart rate dropped from the 250 to 300 range down to a normal 120 to 130 beats per minute, and the hydrops resolved within three weeks.9Clinical Case Reports. Successful Management of Fetal Supraventricular Tachycardia With Flecainide in a Case Complicated by Early Hydrops Fetalis: A Case Report
The long-term outlook for babies treated for fetal SVT is reassuring on the neurological front. A follow-up study found that neurodevelopmental outcomes were normal in all SVT survivors, with the single exception of one child whose issues were caused by a birth injury unrelated to the arrhythmia.10PubMed. Long-term neurodevelopmental outcome after fetal arrhythmia
Stopping an SVT Episode
When a newborn is in SVT, the immediate goal is to break the re-entry circuit and restore a normal rhythm. Treatment escalates through several steps depending on how the baby responds and how stable they are.
The first thing clinicians often try is a vagal maneuver. In newborns, the most effective version involves applying a bag of ice water briefly to the face, which triggers the diving reflex and stimulates the vagus nerve, slowing conduction through the heart’s electrical system. One study found this technique restored normal rhythm in 27 out of 28 attempts.11PubMed. Application of ice water to the face in initial treatment of supraventricular tachycardia It sounds alarming, but the ice is held against the face for only a few seconds and the technique is considered safe and repeatable.
If vagal maneuvers fail, the standard drug treatment is adenosine, given as a rapid intravenous push. Adenosine works by briefly blocking conduction through the AV node, interrupting the re-entry loop. The effect lasts only seconds, which is why it must be pushed quickly and followed by a saline flush. It has become the drug of choice for neonatal SVT.12PubMed. Adenosine administration for neonatal SVT A common approach starts at a low dose and increases incrementally until the rhythm converts. Sometimes the first dose does not work and a second is needed, as was the case in one newborn diagnosed with SVT at delivery who converted only after a second dose of adenosine.13PubMed Central. Unexpected Rhythm: Supraventricular Tachycardia Unveiled in a Neonate Diagnosed at Delivery
Getting intravenous access in a tiny newborn can itself be a challenge. In emergencies where a standard IV cannot be placed, adenosine has been successfully given through an intraosseous line, which is a needle placed directly into the bone marrow.14The Turkish Journal of Pediatrics. Successful intraosseous adenosine administration in a newborn infant with supraventricular tachycardia A single-syringe technique, where adenosine and saline are premixed and pushed together, has also been shown to work in neonates and can simplify the rapid-push requirement.15PubMed Central. A Case Report of Neonatal Supraventricular Tachycardia Resolved with Single-Syringe Adenosine
When Adenosine Is Not Enough
Some episodes resist both vagal maneuvers and adenosine. In these refractory cases, the next steps may include intravenous amiodarone or, if the baby is becoming hemodynamically unstable, synchronized electrical cardioversion. Cardioversion delivers a carefully timed, low-energy electrical shock to the heart to reset its rhythm. Guidelines recommend starting at 0.5 joules per kilogram and escalating to 1 or 2 joules per kilogram if needed.16Indian Pacing and Electrophysiology Journal. Antiarrhythmic therapy for narrow QRS supraventricular tachyarrhythmias in newborns and infants in the first year of life: Potent tools to be handled with care
One case report illustrates how aggressive management sometimes needs to be. A newborn whose SVT hit 301 beats per minute did not respond to three rounds of adenosine or three loading doses of amiodarone. An initial cardioversion at 0.5 joules per kilogram also failed. A second shock at 1 joule per kilogram finally restored normal rhythm.17PubMed Central. Synchronized cardioversion resolving refractory supraventricular tachycardia in a neonate: a case report with comprehensive analysis Cases like this are uncommon, but they underscore why neonatal SVT sometimes requires treatment in an intensive care setting with a full range of interventions available.
Keeping SVT From Coming Back
After an acute episode is broken, the question becomes whether the baby needs ongoing medication to prevent recurrences. Most do, at least for a while. The most commonly used maintenance drugs include beta-blockers like propranolol, digoxin, and in drug-resistant cases, agents like flecainide, propafenone, or amiodarone.
A randomized trial comparing digoxin to propranolol in infants with SVT found that recurrence rates were similar between the two: about 19% on digoxin and 31% on propranolol, a difference that was not statistically significant. No first recurrences happened after 110 days on either drug, and no serious adverse events were reported.18Circulation: Arrhythmia and Electrophysiology. The Study of Antiarrhythmic Medications in Infancy (SAMIS) This suggests that both are reasonable first choices, and the decision between them often comes down to the specific type of SVT and clinician preference.
A larger retrospective study found that about 70% of infants achieved arrhythmia control with a single medication. Another 21% needed two drugs, and 6% required three.19Pediatric Cardiology. Antiarrhythmic Medication in Neonates and Infants with Supraventricular Tachycardia Flecainide has proven useful in cases that do not respond to first-line therapy. A small case series of infants with resistant SVT found that oral flecainide controlled the arrhythmia effectively, with only a few recurrences that responded to dose increases over a two-year follow-up.20PubMed Central. Oral flecainide is effective in management of refractory tachycardia in infants
Medication is typically continued for six to twelve months, then gradually stopped. The rationale is rooted in how the heart develops: the fibrous tissue separating the atria from the ventricles matures during the first year of life, and the accessory pathways responsible for most neonatal SVT tend to disappear on their own during this period.21PubMed Central. Effective Control of Supraventricular Tachycardia in Neonates May Requires Combination Pharmacologic Therapy After stopping medication, about three-quarters of infants remain free of arrhythmias.22Pediatric Cardiology. Antiarrhythmic Medication in Neonates and Infants with Supraventricular Tachycardia
What Happens If SVT Goes Untreated
A brief, self-terminating episode of SVT may cause no lasting harm. But prolonged or frequently recurring episodes can weaken the heart muscle over time, a condition called tachycardia-induced cardiomyopathy. The heart’s pumping function deteriorates simply because it has been running too fast for too long. The encouraging aspect of this complication is that it is reversible: once the fast rate is controlled, heart function typically recovers.23BMJ Case Reports. Tachyarrhythmia-induced cardiomyopathy in a neonate
This is why recognition matters so much. A baby whose SVT goes unnoticed for hours or days can develop heart failure, with fluid buildup, poor feeding, and lethargy that may mimic sepsis or other neonatal illnesses. Early detection and treatment prevent this cascade, and the vast majority of affected newborns recover completely.
Catheter Ablation in Infancy
Most infants with SVT are managed with medication alone. Catheter ablation, a procedure that destroys the abnormal electrical pathway using heat or cold energy delivered through a catheter threaded into the heart, is generally reserved for cases where drugs fail or the arrhythmia is life-threatening.24Circulation. Radiofrequency Catheter Ablation in Infants ≤18 Months Old
There are good reasons for this cautious approach. The hearts of newborns are tiny, and ablation in small hearts carries risks that are lower in older children and adults, including potential damage to coronary arteries, heart valves, and blood vessels.25Netherlands Heart Journal. Radiofrequency ablation of supraventricular tachyarrhythmias in newborns and infants: why, when, and how? Rare cases of procedure-related death have been reported in the literature.26The American Journal of Cardiology. Efficacy and safety of radiofrequency ablation in infants and young children < 18 months of age Advances in mapping technology and growing expertise have improved outcomes, but large-scale studies in babies under one year remain scarce. The general philosophy is to use medication to bridge the infant through the first year, hoping the pathway disappears on its own, and consider ablation only when medical therapy has clearly failed.
Dosing Challenges in Tiny Patients
Treating arrhythmias in newborns involves a unique pharmacological challenge. A newborn’s heart muscle is immature, which means arrhythmias can cause more severe hemodynamic consequences than they would in an older child or adult. At the same time, treatment options are limited by the baby’s size, the difficulty of intravenous access, and the fact that drug metabolism in neonates differs substantially from older patients.27Circulation. Pharmacological Management of Cardiac Arrhythmias in the Fetal and Neonatal Periods: A Scientific Statement From the American Heart Association
Many anti-arrhythmic drugs used in infants were originally developed and studied in adults, and their use in neonates is guided more by clinical experience than by large randomized trials. Kidney and liver function change rapidly in the first weeks of life, affecting how drugs are broken down and cleared. This means doses must be carefully calculated by weight and frequently adjusted. Some medications carry specific risks in this age group: propafenone, for example, was discontinued in a meaningful share of infants in one study because it caused widening of the QRS complex on the ECG.28Pediatric Cardiology. Antiarrhythmic Medication in Neonates and Infants with Supraventricular Tachycardia The long-term developmental effects of exposing a newborn brain to anti-arrhythmic medication remain an area with limited data.
Home Monitoring After Discharge
Once a baby with SVT is stabilized and started on maintenance medication, families face months of vigilance at home. Parents are typically taught to check the baby’s heart rate and to watch for signs of a recurrence. Some families have turned to consumer-grade wearable monitors for added reassurance.
A study of 133 infants with SVT found that about 23% of families used a consumer smart sock device to monitor heart rate at home. These families ended up calling the clinic more and visiting the emergency department more often, which might sound like a downside. But there was an upside: when smart sock users did present to the emergency department with a recurrence, the babies tended to have better-preserved heart function and shorter hospital stays by an average of 1.7 days compared to non-users.29PubMed. Resource Use and Clinical Outcomes in Infants with Supraventricular Tachycardia Monitored with the Owlet Smart Sock The implication is that earlier detection of recurrences, even at the cost of some extra healthcare contact, led to earlier treatment and less heart strain.
Wearable ECG technology is also evolving in the pediatric space. Smartwatch-based ECG recordings have been tested even in preterm neonates in the intensive care unit, and patch-based monitors designed to capture the detailed electrical patterns of the heart have shown promise in infants weighing under 10 kilograms. In one evaluation, monitoring results from a patch device led to changes in clinical management in roughly 30% of patients.30PubMed Central. Wearable and Portable Electrocardiographic Devices as Modern Cardiac Telemetry Solutions in Pediatrics: A Systematic Review These technologies are not yet standard of care for neonatal SVT, but they suggest a future where outpatient rhythm monitoring in babies becomes more practical.
The Genetics Behind Neonatal SVT
Most cases of neonatal SVT arise from accessory pathways that are essentially structural quirks of heart development, and the majority do not have a clear single-gene cause. However, the genetic picture is not entirely blank. Research into the molecular basis of SVT has found that mutations in ion channel genes and signaling pathways are associated with various types of SVT.31PubMed Central. A New Mechanism of Supraventricular Tachycardia: Gene Mutation
A study of neonatal arrhythmias in a neonatal intensive care unit found that among infants with tachyarrhythmias, about 22% had an identifiable genetic cause. The yield was much higher for ventricular tachycardia specifically, where all five affected newborns had identifiable genetic defects.32PubMed Central. Clinical and genetic spectrum of neonatal arrhythmia in a NICU For SVT specifically, the genetic contribution is less clear-cut, but there is growing recognition that certain familial patterns exist. Genetic arrhythmia conditions like congenital long-QT syndrome are classified alongside SVT and ventricular tachycardia as nonbenign neonatal arrhythmias that require active management.33PubMed Central. Neonatal arrhythmias: diagnosis, treatment, and clinical outcome
Genetic testing is not routinely performed for straightforward neonatal SVT, but it may be considered when the arrhythmia is unusually resistant to treatment, presents alongside structural heart defects, or when there is a family history of arrhythmias or sudden cardiac events. The field is still catching up to what the genetics mean in practical terms for treatment decisions.
Wolff-Parkinson-White Syndrome in Newborns
Wolff-Parkinson-White (WPW) syndrome deserves its own mention because it is the most well-known condition associated with neonatal SVT. In WPW, the accessory electrical pathway between the atria and ventricles is visible on a resting ECG as a characteristic “delta wave” pattern, even when the baby is not in SVT. Not every newborn with SVT has WPW, and not every baby with a WPW pattern on ECG will develop SVT, but the two overlap frequently.
Historical data on WPW management in infancy showed that digoxin successfully restored normal rhythm in about 88% of treated infants, and electrical cardioversion worked in about 87% of those who needed it.34PubMed. Wolff-Parkinson-White syndrome and supraventricular tachycardia during infancy: management and follow-up One important nuance: the use of digoxin in WPW has become more controversial over the years because of a theoretical risk that it could speed conduction over the accessory pathway, potentially worsening certain arrhythmias. Current practice varies, and some centers avoid digoxin in confirmed WPW, preferring beta-blockers or other agents. This is an area where you would want your baby’s specific management guided by a pediatric cardiologist who knows the details of the ECG pattern.
The good news applies to WPW as well: the accessory pathway often disappears as the heart matures during the first year. A smaller fraction of babies with WPW will have persistent pathways and may eventually need catheter ablation later in childhood, but that decision can typically wait until the child is older and the procedure is safer.